No­var­tis' San­doz splurges on a trio of GSK an­tibi­otics, dou­bling down with a $500M bet on a field strug­gling to com­bat re­sis­tant mi­crobes

Most ma­jor drug­mak­ers over the past few years have fled the an­tibi­otics space, which has been dou­bly hit by re­sis­tant “su­per bugs” and scarce in­no­va­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.